Itraconazol Stada (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By preventing ergosterol formation, the drug compromises the integrity of the fungal cell membrane, leading to increased permeability and inhibition of fungal growth and replication.

The specific dose of Itraconazol Stada is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes while minimizing adverse effects.

Safety data for itraconazole in pregnancy are limited, and the drug should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider before use.

To request Itraconazol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Itraconazole generally has a broader spectrum against molds such as Aspergillus and dimorphic fungi, whereas fluconazole is more active against Candida species but less effective for many systemic mycoses. Itraconazole also has a higher potential for drug‑drug interactions due to strong CYP3A4 inhibition.

Store Itraconazol Stada at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Itraconazol Stada is taken orally, usually with food or a full glass of water to enhance absorption. The tablet or capsule should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, cardiac failure in patients with pre‑existing heart disease, and QT‑interval prolongation that may lead to arrhythmias. Patients should be monitored for signs of liver injury, rash, or cardiac symptoms during therapy.

Itraconazol Stada is contraindicated in patients with known hypersensitivity to itraconazole or any azole antifungal, in those with severe liver impairment, and in individuals with a history of ventricular dysfunction or uncontrolled heart failure. Caution is also advised for patients taking strong CYP3A4 inducers.